Anavex Receives FDA Clearance for Blarcamesine Fragile X Study
Anavex said its IND application for blarcamesine in Fragile X syndrome has received FDA clearance. A Phase 2a study will evaluate safety, tolerability and pharmacokinetics in adult males.